Skip to main content
Lia Gore, MD, Pediatric Hematology & Oncology, Aurora, CO, University of Colorado Hospital

LiaGoreMD

Pediatric Hematology & Oncology Aurora, CO

Professor of Pediatrics, Medical Oncology, and Hematology, University Colorado

Dr. Gore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gore's full profile

Already have an account?

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Pediatric Hematology/Oncology, 1996 - 2001
  • University of Colorado
    University of ColoradoResidency, Pediatrics, 1994 - 1996
  • Children's National Medical Center
    Children's National Medical CenterInternship, Pediatrics, 1993 - 1994
  • George Washington University School of Medicine and Health Sciences
    George Washington University School of Medicine and Health SciencesClass of 1993
  • Carleton College
    Carleton CollegeB.A., Psychology, 1987

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 1995 - 2025
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Top Docs Award 5280 Magazine, 2012, 2014-2020
  • Regional Top Doctor Castle Connolly, 2014
  • Disruptive Innovators in Research Excellence University of Colorado School of Medicine, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase I Combination Study of Trabectedin and Capecitabine in Patients With Advanced Malignancies  
    Gore L, Rivera E, Basche M, Moulder SL, LaVallee K, Li J, Sarah Eppers S, Grolnic S, O'Bryant CL, Cleere D, Elsayed YA, Eckhardt SG, Investigational New Drugs, 1/1/2011
  • A phase I study of weekly R1507 - a human monoclonal antibody insulin-like growth factor receptor-1 antagonist - in patients with advanced solid tumors  
    Kurzrock R, Mitta AC, Ainser J, Eid JE, Greig G, Habben K, McCarthy CD, Eckhardt SG, Gore L, Clinical Cancer Research, 1/6/2010
  • Challenges and Controversies in Early-phase Pediatric Oncology Clinical Trials: Who, How, Why, and What ?  
    Gore L and Eckhardt SG, ASCO News and Forum, 1/1/2009
  • Join now to see all

Abstracts/Posters

  • Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    Lia Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
    Lia Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...
    Lia Gore, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Expanding Horizons for Immunotherapy in Pediatric Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Podcast: CU Anschutz Powers up for Regenerative Medicine Frontier
    Podcast: CU Anschutz Powers up for Regenerative Medicine FrontierMay 9th, 2023
  • Rubio, Bennet Introduce Bill to Boost Pediatric Cancer Research Through Combination Drug Trials
    Rubio, Bennet Introduce Bill to Boost Pediatric Cancer Research Through Combination Drug TrialsMay 13th, 2022
  • CU Cancer Members Recognized for Contributions to Immunotherapy in Pediatric Cancer
    CU Cancer Members Recognized for Contributions to Immunotherapy in Pediatric CancerJune 23rd, 2021
  • Join now to see all

Grant Support

  • COG NCTN Network Group Operations CenterNational Cancer Institute2019–2025
  • Agent Prioritization CommitteeNational Cancer Institute2018–2023
  • Cancer Center Support Grant, Senior LeadersNational Cancer Institute1997–2022
  • Eliminating Disparities in Patients with Acute LeukemiasUniversity of Colorado Cancer Center2020–2021

Professional Memberships

Hospital Affiliations